Gold Nest Capital participated in BIO International 2023 in Boston
Boston, June 8, 2023 – Mrs Ginger Hsiao, Chief Investment Officer and Partner of Gold Nest Capital, took part in the BIO International Convention held in Boston from June 5 to 8, 2023. Mrs Hsiao shared…
Gold Nest Capital & BTI from A*STAR present the Enabling Biotech 2022 seminar
Singapore, October 18, 2022 – Gold Nest Capital and Bioprocessing Technology Institute from A*STAR (Agency for Science, Technology and Research) jointly present the Enabling Biotech 2022 seminar – Breakthrough Technologies for Biomanufacturing and Cell & Gene…
Gold Nest Capital & Ginward participate in the BioJapan 2022 conference in Yokohama
Yokohama, October 12, 2022 – Ginward and Gold Nest Capital participate in the 2023 edition of BioJapan, the Asia’s premier event for the global biotechnology industry. Featuring a twinned exhibition, seminars and a large-scale partnering…
Biosana enters exclusive global licensing agreement with Alvotech for co-development of a Proposed Biosimilar (AVT23) to Xolair® (Omalizumab)
Leiden, February 2, 2022 – BiosanaPharma, a Gold Nest Capital portfolio company, has entered into a global licensing agreement with Alvotech to co-develop BP001, a biosimilar of Xolair (omalizumab). Under this agreement, BiosanaPharma and Alvotech…
Insights on the Biochips Global Market to 2026
Dublin, December 20, 2021 – The global biochips market exhibited strong growth during 2015-2020. Looking forward, the market is expected to grow at a CAGR of around 15% during 2021-2026. Keeping in mind the uncertainties…
MIMETAS wins Deshima award for Dutch-Japanese business relations
Leiden & Tokyo, June 7, 2021 – MIMETAS has been awarded the “Deshima Business Award” in the category “newly established” by the Netherlands Chamber of Commerce in Japan (NCCJ), and the Embassy of the Kingdom…
MIMETAS and Roche Enter into a Collaboration to Develop Human Disease Models for Drug Development
Leiden, July 6, 2021 – MIMETAS, a leader in organ-on-chip-based disease models and technology, and Roche, a world-leading pharmaceutical company, announced today that they have entered into a collaboration to develop human disease models to…
Nature Communication publishes application of switchSENSE technology in multivalent antibody development
Leiden, July 18, 2021 – Today, Andreas Plückthun’s group at the University of Zurich publishes on Nature Communication with the help of switchSENSE technology. The paper shows that an engineered anti-Her2 tetravalent antibody construct that…
UK eases the way to market for biosimilars
Today, UK’s Medicines & Healthcare products Regulatory Agency (MHRA) published the final guidance on the licensing of biosimilar products, lowering the barrier for biosimilar drug to enter the market. Today’s final version follows draft guidelines…
Conformation analysis realized by switchSENSE published in Proceedings of National Academy of Science
La Jolla, LA, March 30, 2021 – Litao Sun, et al, at Scripps Research used the switchSENSE® technology in their paper to analyze the different conformations of the wild-type and mutant versions of the alanyl-tRNA…